A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease

This publication has 22 references indexed in Scilit:

• Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
  Neurology, 2009
• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
  The Lancet, 2007
• A Dose-Ranging Study of AAV-hAADC Therapy in Parkinsonian Monkeys
  Published by Elsevier ,2006
• Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
  Molecular Therapy, 2006
• Gene therapy for Parkinson’s disease using recombinant adeno-associated viral vectors
  Expert Opinion on Biological Therapy, 2005
• Evolution of the response to levodopa during the first 4 years of therapy
  Annals of Neurology, 2002
• Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral Vectors Expressing Dopamine-Synthesizing Enzymes
  Human Gene Therapy, 2002
• Functional Effect of Adeno-associated Virus Mediated Gene Transfer of Aromatic L-Amino Acid Decarboxylase into the Striatum of 6-OHDA-Lesioned Rats
  Molecular Therapy, 2001
• Triple Transduction with Adeno-Associated Virus Vectors Expressing Tyrosine Hydroxylase, Aromatic-L-Amino-Acid Decarboxylase, and GTP Cyclohydrolase I for Gene Therapy of Parkinson's Disease
  Human Gene Therapy, 2000
• The long-duration response to l -dopa in the treatment of early PD
  Neurology, 2000